SLC2A1 and breast cancer: GLUT1 is an important target in cancer therapy, and its inhibition may represent an effective approach to overcoming cancer cell resistance; the small molecule WZB117 inhibits GLUT1 expression and sensitizes breast cancer cells to ionizing radiation [49].